Is stem cell therapy abroad safe and legal? Learn what the NeuroGen deregistration controversy reveals about clinic regulation, patient safety, evidence, candidacy, and what’s not yet proven.
Stem cell therapy is regulated differently in each country. The controversy over NeuroGen's deregistration highlights that even if a therapy isn’t routinely approved in one country, it may operate legally under strict medical frameworks elsewhere—like in Türkiye. Safety depends on rigorous oversight, clinic credentials, and transparent processes, not on the absence of news headlines.
Living with a chronic condition or progressive neurological disease means navigating hope, worry, and—often—limited standard options. Many find stem cell therapy after exhausting conventional routes, searching for real improvement and second opinions. Media reports about clinics facing regulatory scrutiny, like NeuroGen's recent dispute, understandably make patients question: Can these treatments really help? Are they trustworthy? Will I be safe if I travel for care?
NeuroGen recently received a deregistration notice from the Navi Mumbai Municipal Corporation (NMMC), prompting debate about clinic standards, evidence requirements, and patient safety protocols. This situation underscores the evolving global landscape: while some clinics face sanctions over documentation, transparency, or advertising, others—operating under strict national frameworks—continue offering regulated care. It is not enough for a therapy to be simply available; it must also be supervised, evidenced to a reasonable standard, and accountable to health authority guidelines.
A therapy is 'controversial' when its claims or practices don’t meet accepted scientific or ethical standards—think unverified claims, lack of transparency, or incomplete documentation. 'Investigational' therapies, by contrast, are part of formal, physician-led protocols monitored under national health regulations. In the Istanbul clinic context, therapies are reviewed under TİTCK (Turkish Medicines and Medical Devices Agency) oversight, with protocols reviewed, cell sources documented, and results tracked for safety.
Regulated clinics must prove more than just a license. In our Istanbul setting, umbilical cord-derived MSCs are processed in facilities aligned with GMP (Good Manufacturing Practice) principles, independently screened for infectious disease, and identity-verified via CD73, CD90, and CD105 markers. Each batch is subject to sterility, viability, and endotoxin testing before release—never taken for granted. International documentation and medical records review is standard before any appointment or intervention.
MSC therapies focus on their paracrine effects—chemical messaging that supports neighbouring cells—and immunomodulation, helping to regulate abnormal inflammation. Signals released by MSCs, such as BDNF (brain-derived neurotrophic factor), TGF-β, NGF, and VEGF, are studied for their roles in nerve repair, inflammation dampening, and tissue support. According to Prof. Dr. Serdar Kabataş, MD, PhD (C), such mechanisms are best understood as supportive, not curative. Clinical research over the past 15+ years has mapped out these biological effects in conditions including multiple sclerosis and degenerative spinal disease, but careful patient selection and specialist follow-up remain essential.
Not every patient is a candidate for stem cell or exosome therapy. Suitability requires a full medical review: diagnosis, functional status, comorbidities, medications, and current disease stage. Patients with acute infections, active cancer, severe organ failure, or unrealistic expectations are generally not offered treatment. Candidacy may open for those with stable neurological conditions, chronic degeneration, or who have exhausted mainstream options but remain medically stable. A responsible clinic makes this call only after a multidisciplinary assessment.
All MSCs used in our protocols come from accredited, ethically donated umbilical cords, cryopreserved at –196°C, and batch-screened for HIV, HBV, HCV, CMV, EBV, mycoplasma, and endotoxins. GMP-aligned processing ensures traceability and documentation at every stage. Identity verification—using expression of CD73, CD90, and CD105 markers—adds another safety layer. Patients may request documentation at each step, and a copy of the cell product's quality certificate is provided.
Most patients will not see immediate results—expect gradual changes over 3–6 months, sometimes continuing for up to a year. Clinical changes may include pain reduction, modest functional improvement, or increased stamina. There are no guarantees: improvement ranges from none, to modest, to meaningful. It is not a substitute for established therapies. For a few, no measurable effect is seen; for others, symptoms stabilize or modestly improve—especially when combined with rehabilitation or physiotherapy.
No, a clinic’s deregistration (such as NeuroGen’s notice) usually reflects specific concerns about that provider’s compliance, documentation, or claims—not about the safety of stem cell science as a whole. Safe clinics follow rigorous regulatory, documentation, and quality standards under their country’s health authority.
Ask directly: which health authority licenses them? Do they provide GMP documentation, infection screening certificates, and medical records? In Türkiye, TİTCK oversight guarantees compliance with national medical standards for permitted conditions and protocols.
Yes—international patients follow the clinic’s protocol under TİTCK regulation. Turkish citizens, by contrast, require an individual permit from the Ministry of Health (Sağlık Bakanlığı) for non-standard cell therapy.
Not all are equally experimental. Mesenchymal stem cell therapy has 15+ years of published research across many conditions, but many real-world uses—especially outside standard indications—are still considered investigational. Exosome therapy is newer and typically less established, though regulated facilities follow strict safety and consent standards.
Stem cell therapy is typically offered as an adjunct—supportive, not a replacement. Conventional care for neurological or degenerative disease (medication, rehabilitation, surgery) remains first-line. Stem cells may help support tissue repair or reduce inflammation, but evidence varies.
With regulated, GMP-processed MSCs and documented infectious screening, the risk is very low. Unregulated clinics or clinics that will not produce cell source documentation should be avoided. Minor reactions (fever, headache) can occur but are usually short-lived.
Yes. Stem cell therapy does not replace your prescribing physician or neurologist. Coordination and transparency among all your care providers is safest.
Request protocol details, safety certificates, donor and infectious screening documents, GMP compliance proof, and your full clinical evaluation file. This is standard for reputable clinics serving international patients.
Clinic deregistration cases warn us to avoid hype and shortcuts. Stem cell therapy, when delivered under national medical standards, with real documentation and honest expectations, may support—but not replace—your existing care. At our Istanbul clinic, a Free Consultation includes a detailed medical assessment, eligibility confirmation, and open discussion of what we can deliver—no high-pressure tactics or guaranteed outcomes. Real medicine, not marketing. Book your Free Consultation and let our team help clarify your options.
Stem Cell Therapy Controversy: What Clinic Deregistration Cases Mean for Patients Considering Treatment Abroad